A Clinical Trial With Chimeric Monoclonal Antibody WX-G250 and Low Dose Interleukin-2 Pulsing Scheme for Advanced Renal Cell Carcinoma
作者： I. Bleumer , E. Oosterwijk , J.C. Oosterwijk-Wakka , M.C.W. Völler , S. Melchior
DOI: 10.1016/S0022-5347(05)00040-6
关键词: Oncology 、 Antibody 、 Carcinoma 、 Immunology 、 Kidney cancer 、 Monoclonal antibody 、 Medicine 、 Internal medicine 、 Progressive disease 、 Immunotherapy 、 Renal cell carcinoma 、 Antibody-dependent cell-mediated cytotoxicity
摘要: Purpose: WX-G250 is a chimeric monoclonal antibody that binds to carbonic anhydrase IXG250/MN, which present on greater than 95% of RCCs the clear cell subtype. The suggested working mechanism by ADCC. Because number activated ADCC effector cells can be increased low dose interleukin-2 pulsing schedule, multicenter study was initiated investigate whether combined with LD-IL-2 could lead an improved clinical outcome in patients progressive RCC.Materials and Methods: A total 35 RCC received weekly infusions for 11 weeks daily regimen. Patients were monitored longitudinally capacity. Radiological assessment metastatic lesions performed at week 16 regularly until disease progression.Results: durable benefit achieved 8 (23%), including 3 partial response 5 stabilization 24 or greater. Mean survival 22 mo...
ru.nl
elsevier.com
jurology.com 参考文章(18)
Steven A. Rosenberg, Gwendolyn Fyfe, Gwendolyn Fyfe, Richard I. Fisher, Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. The cancer journal from Scientific American. ,vol. 6, ,(2000)
R. J. Motzer, B. I. Rini, M. D. Michaelson, B. G. Redman, G. R. Hudes, G. Wilding, R. M. Bukowski, D. J. George, S. T. Kim, C. M. Baum, Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) Journal of Clinical Oncology. ,vol. 23, pp. 4508- 4508 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.4508
George Sgouros, Chaitanya R. Divgi, Joseph A. O'Donoghue, Devie Deland, Sydney Welt, Sydney Welt, Andrew M. Scott, Andrew M. Scott, Seza Gulec, Aparna Nakhre, Lloyd J. Old, Lloyd J. Old, Francesca Morrissey, Martin C. Graham, Jeanne M. Williams, Peter Capitelli, Neil H. Bander, Neil H. Bander, Neil H. Bander, Egbert Oosterwijk, Egbert Oosterwijk, Ronald D. Finn, Steven M. Larson, Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clinical Cancer Research. ,vol. 4, pp. 2729- 2739 ,(1998)
J Baselga, Clinical trials of Herceptin® (trastuzumab) European Journal of Cancer. ,vol. 37, pp. 18- 24 ,(2001) , 10.1016/S0959-8049(00)00404-4
H Uemura, Y Nakagawa, K Yoshida, S Saga, K Yoshikawa, Y Hirao, E Oosterwijk, MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. British Journal of Cancer. ,vol. 81, pp. 741- 746 ,(1999) , 10.1038/SJ.BJC.6690757
E. Oosterwdk, D. J. Ruiter, Ph. J. Hoedemaeker, E. K. J. Pauwels, U. Jonas, I. Zwartendijk, S. O. Warnaar, Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. International Journal of Cancer. ,vol. 38, pp. 489- 494 ,(1986) , 10.1002/IJC.2910380406
Todd A. Fehniger, James Hitt, Michael A. Caligiuri, N. J. Meropol, Grace M. Barresi, Margaret Franklin, Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunology, Immunotherapy. ,vol. 46, pp. 318- 326 ,(1998) , 10.1007/S002620050493
Jean E. Surfus, Jacquelyn A. Hank, Egbert Oosterwijk, Sydney Welt, Mary J. Lindstrom, Mark R. Albertini, Joan H. Schiller, Paul M. Sondel, Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. Journal of Immunotherapy. ,vol. 19, pp. 184- 191 ,(1996) , 10.1097/00002371-199605000-00003
James C. Yang, Leah Haworth, Richard M. Sherry, Patrick Hwu, Douglas J. Schwartzentruber, Suzanne L. Topalian, Seth M. Steinberg, Helen X. Chen, Steven A. Rosenberg, A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer The New England Journal of Medicine. ,vol. 349, pp. 427- 434 ,(2003) , 10.1056/NEJMOA021491
Ivar Bleumer, Egbert Oosterwijk, Pieter De Mulder, Peter F.A. Mulders, Immunotherapy for Renal Cell Carcinoma European Urology. ,vol. 44, pp. 65- 75 ,(2003) , 10.1016/S0302-2838(03)00191-X